Please assess the completion status of the following clinical trial:

Trial Title: Transition From Alendronate to Romosozumab (AMG 785)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal women, defined as no vaginal bleeding or spotting for ≥ 12 months~* Low bone mineral density at screening \[defined by a bone mineral density (BMD) T-score ≤ -2.0 and ≥ -4.0 at the lumbar spine (L1 to L4; or BMD T-score of evaluable vertebrae), total hip, or femoral neck\]~* Currently taking alendronate (70 mg weekly or equivalent) exclusively for ≥ 1 year with verbal agreement that the subject has taken ≥ 80% of their doses with good tolerance~Exclusion Criteria:~* History of vertebral fracture, or fragility fracture of the wrist, humerus, hip or pelvis after age 50; or recent bone fracture within 6 months prior to screening~* History of metabolic or bone disease such as Paget's disease, rheumatoid arthritis, osteomalacia, osteogenesis imperfecta, osteopetrosis, ankylosing spondylitis, Cushing's disease, hyperprolactinemia, and malabsorption syndrome~* Vitamin D deficiency (defined as 25-OH-VitD levels \< 20 ng/mL)

- Gender: FEMALE
- Minimum Age: 55 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Romosozumab 140 mg (Type: EXPERIMENTAL): Participants received romosozumab 140 mg administered subcutaneously once a month for 3 months.
- Romosozumab 210 mg (Type: EXPERIMENTAL): Participants received romosozumab 210 mg administered subcutaneously once a month for 3 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).